Literature DB >> 31127022

Uterine and Cervical Adenosarcoma: A Retrospective Study of Overall Oncologic Outcomes and Fertility Preservation in Early-Stage Disease.

Zhen Yuan1, Dongyan Cao1, Mei Yu2, Keng Shen1, Yonglan He3.   

Abstract

BACKGROUND: The management of adenosarcoma is based on the limited available data. This study aimed to explore the characteristics and oncologic outcomes of patients with uterine and cervical adenosarcoma.
MATERIALS AND METHODS: A total of 21 and 32 cases of cervical and uterine adenosarcoma, respectively, were retrospectively reviewed in Peking Union Medical College Hospital between April 2006 and March 2019.
RESULTS: The median follow-up time was 37.5 months (range, 1-153 months). The disease progression rate (DPR) was significantly higher in patients with uterine adenosarcoma compared with those with cervical adenosarcoma (28.1% vs. 4.8%). The curve of progression-free survival significantly differed. For those with cervical adenosarcoma, the presence of a tumor stalk was a protective factor, whereas heterologous elements (HE) presented a risk factor for disease progression. For those with uterine adenosarcoma, the presence of a tumor stalk was an independent protective factor, whereas lymphovascular space invasion (LVSI) was an independent risk factor for disease progression. Moreover, HE was an independent risk factor for mortality. Fertility-sparing surgery (FSS) was performed in four and five patients with cervical and uterine adenosarcoma, respectively. Regarding FSS, combined with cases in previous studies, the DPR of patients with uterine adenosarcoma was relatively higher compared with those with cervical adenosarcoma.
CONCLUSION: We found that cervical adenosarcoma had a better prognosis than uterine adenosarcoma. The presence of a tumor stalk was a protective factor, whereas HE and LVSI were risk factors for prognosis. For those with uterine adenosarcoma, if FSS was administered, robust evaluation would be necessary. The small sample size limits the ability to make any strong conclusions about FSS. IMPLICATIONS FOR PRACTICE: Uterine cervical adenosarcoma had a better prognosis than uterine adenosarcoma. For patients with cervical adenosarcoma, the presence of a tumor stalk was a protective factor and the presence of heterologous elements (HE) was a risk factor for disease progression. For those with uterine adenosarcoma, the presence of a tumor stalk was a protective factor and lymphovascular space invasion was a risk factor for disease progression. Moreover, HE was a risk factor for mortality. Regarding fertility-sparing surgery (FSS), the disease progression rate was higher in patients with uterine adenosarcoma compared with those with cervical adenosarcoma. For patients with uterine adenosarcoma, if FSS was administered, hysteroscopy and robust imaging evaluation would be necessary. © AlphaMed Press 2019.

Entities:  

Keywords:  Adenosarcoma of the uterus; Cervix uteri; Fertility preservation

Year:  2019        PMID: 31127022      PMCID: PMC6738297          DOI: 10.1634/theoncologist.2018-0791

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  23 in total

1.  Robotically assisted total laparoscopic radical trachelectomy for fertility sparing in stage IB1 adenosarcoma of the cervix.

Authors:  John P Geisler; Curtis J Orr; Kelly J Manahan
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2008-10       Impact factor: 1.878

2.  Vaginal mass in a 13-year-old girl.

Authors:  Sarat Kumar Sanamandra; May Ying Leong; Marielle V Fortier
Journal:  Ann Acad Med Singapore       Date:  2014-02       Impact factor: 2.473

3.  Significance of lymph node metastasis on survival of women with uterine adenosarcoma.

Authors:  Hiroko Machida; Michael J Nathenson; Tsuyoshi Takiuchi; Crystal L Adams; Jocelyn Garcia-Sayre; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2017-01-18       Impact factor: 5.482

4.  Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.

Authors:  Alberto Gallardo; Jaime Prat
Journal:  Am J Surg Pathol       Date:  2009-02       Impact factor: 6.394

5.  Adenosarcoma of the uterine cervix: a clinicopathological study of 12 cases.

Authors:  M W Jones; M Lefkowitz
Journal:  Int J Gynecol Pathol       Date:  1995-07       Impact factor: 2.762

6.  Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases.

Authors:  C J Zaloudek; H J Norris
Journal:  Cancer       Date:  1981-07-15       Impact factor: 6.860

7.  Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands.

Authors:  Virginia Benito; Amina Lubrano; Octavio Arencibia; Miguel Andújar; Eva Alvarez; Norberto Medina; Juan Miguel Falcón; Orlando Falcón
Journal:  Int J Gynaecol Obstet       Date:  2009-06-25       Impact factor: 3.561

8.  Mullerian adenosarcoma of the cervix: Report of two large tumors with sarcomatous overgrowth or heterologous elements.

Authors:  Brandon-Luke L Seagle; Keith J Falter; Stephen J Lee; Marina Frimer; Robert Samuelson; Shohreh Shahabi
Journal:  Gynecol Oncol Case Rep       Date:  2014-05-05

9.  Case Report of Successful Childbearing after Conservative Surgery for Cervical Mullerian Adenosarcoma.

Authors:  Seiji Kanayama; Masako Nakamura; Hidekazu Oi; Sumire Sugimoto; Yoshikazu Sasaki; Tomoko Uchiyama; Chiho Ohbayashi; Hiroshi Kobayashi
Journal:  Case Rep Obstet Gynecol       Date:  2017-01-05

10.  Müllerian adenosarcoma of the uterine cervix with sarcomatous overgrowth: A case report of aggressive disease in a young patient.

Authors:  David A Morales F; Monica L Medina R; Lina M Trujillo; Maria I Beltrán; Isabel C Dulcey
Journal:  Int J Surg Case Rep       Date:  2016-09-04
View more
  3 in total

1.  Supraclavicular lymph node metastasis in elderly patients undergoing esophageal squamous cell carcinoma radical surgery: construction of risk and prognostic predictive nomograms.

Authors:  Ling Chen; Shaobin Yu; Xiaohong Jiang; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

2.  Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites.

Authors:  Jessie Y Li; Levent Mutlu; Joan Tymon-Rosario; Wafa Khadraoui; Nupur Nagarkatti; Pei Hui; Natalia Buza; Lingeng Lu; Peter Schwartz; Gulden Menderes
Journal:  Gynecol Oncol Rep       Date:  2021-12-20

3.  Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma.

Authors:  Szymon Piątek; Iwona Szymusik; Anna Dańska-Bidzińska; Mariusz Ołtarzewski; Gabriela Trojan; Mariusz Bidziński
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.